HAI Book 2025 - Flipbook - Page 437
Oliva-Lopez, Delphine
111
Characterizing fluid and cortical tau biomarker expression in typical
and atypical Alzheimer's disease: A comparative study of pTau levels and
tau-PET imaging
Delphine Oliva-Lopez1,2,3, Lydia Trudel1,2,3, Etienne Aumont1,2,3, Nesrine Rahmouni1,2,3, Gleb
Bezgin1,2,3, Tevy Chan1,2,3, Brandon Hall1,2,3, Tharick Pascoal4, Pedro Rosa-Neto1,2,3
1
Montreal Neurological Institute, Montreal, QC, CA
Department of Neurology and Neurosurgery, McGill University, Montreal, QC, CA
3
- Translational Neuroimaging Laboratory, The McGill University Research Center for Studies in Aging, Douglas
Mental Health Institute, Montreal, QC, CA
4
University of Pittsburg, Pittsburg, PA, US
2
Introduction: This project aims to explore fluid pTau expression in typical AD and atypical forms, including
Posterior Cortical Atrophy (PCA) and Primary Progressive Aphasia (PPA). This is to better understand how
different plasma pTau biomarkers are expressed in blood plasma among different AD presentations.
Methods: We analyzed data from 43 Alzheimer9s patients, 339 cognitively normal (CN) elderly, 105 with mild
cognitive impairment (MCI), and 31 atypical AD cases (14 PPA and 17 PCA) from the TRIAD cohort. Statistical
analyses, including boxplots (Fig. 1) were performed in R 4.4.1. The boxplots provide a clear assessment of the
different type of pTau levels (ptau217, pTau181 and pTau 231) across typical and atypical Alzheimer's presentations.
Results: Boxplot analyses revealed elevated plasma pTau in both AD typical and atypical groups compared to the
CN and MCI (p < 0.001), with no significant differences between typical and atypical AD.
Conclusion: Our results suggest that the different plasma pTau biomarkers are expressed the same way in typical
and Atypical ADs. We can therefore use them all as reliable biomarkers in exploring the pathology of typical and
atypical ADs.
Keywords: plasma, tau, PET, PPA, Alzheimers
HAI2025 - 437
